Arbutus Gains on $230M Buyback Using Moderna Settlement Proceeds
Deals·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Arbutus Biopharma Corp. shares are up 14% at market open after the clinical-stage infectious disease biotech company announced the repurchase of up to $230 million of common shares.
The buyback will be funded using proceeds from a settlement with Moderna, which has positively impacted investor sentiment.
Arbutus BiopharmaModerna
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Arbutus Biopharma Corp. shares are up 14% at market open after the clinical-stage infectious disease biotech company announced the repurchase of up to $230 million of common shares.”
Bloomberg — Arbutus Gains on $230m Buyback Using Moderna Settlement Proceeds